• Biogen seeking to shift from solely an MS-identified leader in biotech to a trusted leader in hemophilia
  • The hemophilia community is entrenched with longstanding big-pharma corporate partners
  • Hemophilia patients have been burned before and building trust within their community is difficult and takes time
  • Biogen needed to establish trusted relationships with patients, patient organizations and KOLs in short order as they were expecting approval of two novel therapies within the year